vaccines-world-2017-scientifictracks-abstracts

5 / 15

alliedacademies
Virology Research Journal
Volume 1 Issue 4 Vaccines World 2017
Notes:
Page 17
November 09-10, 2017 Vienna, Austria
21st World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Measles vector vaccine platform as an effective tool to
prevent chikungunya virus infection
Matthias Müllner, Katrin Ramsauer, Andrea Pfeiffer, Raimund Vielnascher,
Christa Firbas and Erich Tauber
Themis Bioscience GmbH, Austria
Themis’ is developing a safe, effective and affordable
preventive vaccine platform against priority pathogen
diseases that have the potential to cause epidemics such as
Chikungunya or Zika virus infection by using a “plug-and
play” vaccine technology.This technology is basedonameasles
vaccine vector (MV) that can be easily genetically modified to
express immunoprotective proteins for designated emerging
infectious pathogens. This delivery platform technology
has already demonstrated proof of principle in humans
through a Phase 1 clinical trial in 42 healthy volunteers with
a recombinant measles vaccine against Chikungunya virus
(MV-CHIK). We showed that the vaccine was well tolerated.
One immunization induced functional, neutralizing
antibodies in up to 90% of immunized subjects, a second
immunization induced 100% seroconversion. Importantly,
immunogenicity was independent of pre-existing anti-vector
(measles) immunity. We show here a Phase 2 clinical trial to
demonstrate the vaccine vector safety and immunogenicity
in up to 300 subjects. Preliminary findings point at excellent
safety and immunogenicity profile in the two doses tested.
Data are currently under final evaluation and auditing, and
will be presented here.
Biography
Matthias Müllner holds a Master’s degree in Molecular Biology from the
University of Vienna and completed his Doctoral studies in 2010 at the
Department of Virology and Biomedicine at the Veterinarian University of Vienna.
He joined Themis Bioscience in 2011 and in his function as Head of CMC,
he was responsible for the development of a stable and robust manufacturing
process for Themis’ Measles based live virus vaccine platform technology.
The respective process was successfully used to manufacture phase 1 and/
or phase 2 clinical batches for vaccines against Chikungunya Virus (MV CHIK),
Dengue Virus (MV DEN) and Zika Virus (MV ZIKA). Currently, the process is
optimized for commercial vaccine production.
Matthias Müllner Xia et al., Virol Res J 2017, 1:4